Lipocine Inc. (NASDAQ:LPCN) traded down 3.7% during trading on Wednesday . The stock traded as low as $3.39 and last traded at $3.41, with a volume of 65,850 shares changing hands. The stock had previously closed at $3.54.

Separately, Canaccord Genuity restated a “buy” rating and set a $6.00 price objective on shares of Lipocine in a report on Wednesday, August 10th.

The company’s 50 day moving average is $3.68 and its 200-day moving average is $7.70. The stock’s market capitalization is $61.53 million.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.05. Analysts expect that Lipocine Inc. will post ($1.31) EPS for the current year.

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.